These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2906214)

  • 1. Brain and CSF somatostatin concentrations in patients with psychiatric or neurological illness. An overview.
    Vecsei L; Widerlöv E
    Acta Psychiatr Scand; 1988 Dec; 78(6):657-67. PubMed ID: 2906214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin in Alzheimer's disease and depression.
    Bissette G; Myers B
    Life Sci; 1992; 51(18):1389-410. PubMed ID: 1357521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid somatostatin and psychiatric illness.
    Rubinow DR
    Biol Psychiatry; 1986 Apr; 21(4):341-65. PubMed ID: 2869790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF somatostatin in Alzheimer's disease and major depression: relationship to hypothalamic-pituitary-adrenal axis and clinical measures.
    Molchan SE; Hill JL; Martinez RA; Lawlor BA; Mellow AM; Rubinow DR; Bissette G; Nemeroff CB; Sunderland T
    Psychoneuroendocrinology; 1993; 18(7):509-19. PubMed ID: 7903467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF somatostatin in patients with Alzheimer's disease, older depressed patients, and age-matched control subjects.
    Sunderland T; Rubinow DR; Tariot PN; Cohen RM; Newhouse PA; Mellow AM; Mueller EA; Murphy DL
    Am J Psychiatry; 1987 Oct; 144(10):1313-6. PubMed ID: 2889377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients.
    Gerner RH; Yamada T
    Brain Res; 1982 Apr; 238(1):298-302. PubMed ID: 6123376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of carbamazepine on cerebrospinal fluid somatostatin.
    Rubinow DR; Post RM; Gold PW; Ballenger JC; Reichlin S
    Psychopharmacology (Berl); 1985; 85(2):210-3. PubMed ID: 2861620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid neuropeptides in mood disorder and dementia.
    Banki CM; Karmacsi L; Bissette G; Nemeroff CB
    J Affect Disord; 1992 May; 25(1):39-45. PubMed ID: 1352520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid vasopressin in neurological and psychiatric disorders.
    Sørensen PS; Gjerris A; Hammer M
    J Neurol Neurosurg Psychiatry; 1985 Jan; 48(1):50-7. PubMed ID: 3973621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF somatostatin in Alzheimer's disease, depressed patients, and control subjects.
    Davis KL; Davidson M; Yang RK; Davis BM; Siever LJ; Mohs RC; Ryan T; Coccaro E; Bierer L; Targum SD
    Biol Psychiatry; 1988 Oct; 24(6):710-2. PubMed ID: 2901865
    [No Abstract]   [Full Text] [Related]  

  • 11. CSF somatostatin in affective illness and normal volunteers.
    Rubinow DR; Gold PW; Post RM; Ballenger JC
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):393-400. PubMed ID: 2866561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients.
    Doran AR; Rubinow DR; Roy A; Pickar D
    Arch Gen Psychiatry; 1986 Apr; 43(4):365-9. PubMed ID: 2869743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular size distribution of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with degenerative brain disease.
    Rissler K; Cramer H; Schaudt D; Strubel D; Gattaz WF
    Neurosci Res; 1986 Feb; 3(3):213-25. PubMed ID: 2871533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders: evidence from CSF and post-mortem studies.
    Nemeroff CB; Bissette G
    Prog Clin Biol Res; 1985; 192():333-41. PubMed ID: 2934745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptides in the cerebrospinal fluid of neuropsychiatric patients: an approach to central nervous system peptide function.
    Post RM; Gold P; Rubinow DR; Ballenger JC; Bunney WE; Goodwin FK
    Life Sci; 1982 Jul; 31(1):1-15. PubMed ID: 6180277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prednisone decreases CSF somatostatin in healthy humans: implications for neuropsychiatric illness.
    Wolkowitz OM; Rubinow DR; Breier A; Doran AR; Davis C; Pickar D
    Life Sci; 1987 Oct; 41(16):1929-33. PubMed ID: 2889125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin in cerebrospinal fluid.
    Cooper PE
    Bull Clin Neurosci; 1985; 50():26-9. PubMed ID: 2876739
    [No Abstract]   [Full Text] [Related]  

  • 18. Preclinical and clinical studies with somatostatin related to the central nervous system.
    Vécsei L; Widerlöv E
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(4):473-502. PubMed ID: 1978375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF somatostatin in Alzheimer's disease.
    Serby M; Richardson SB; Twente S; Siekierski J; Corwin J; Rotrosen J
    Neurobiol Aging; 1984; 5(3):187-9. PubMed ID: 6151123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal-fluid neuropeptides: a biochemical subgrouping approach.
    Banki CM; Karmacsi L; Bissette G; Nemeroff CB
    Neuropsychobiology; 1992; 26(1-2):37-42. PubMed ID: 1361969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.